Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
ContributorsWeitz, Jeffrey I; Lensing, Anthonie W A; Prins, Martin H; Bauersachs, Rupert; Beyer-Westendorf, Jan; Bounameaux, Henri; Brighton, Timothy A; Cohen, Alexander T; Davidson, Bruce L; Decousus, Hervé; Freitas, Maria C S; Holberg, Gerlind; Kakkar, Ajay K; Haskell, Lloyd; van Bellen, Bonno; Pap, Akos F; Berkowitz, Scott D; Verhamme, Peter; Wells, Philip S; Prandoni, Paolo
Published inNew England Journal of Medicine, vol. 376, no. 13, p. 1211-1222
Publication date2017
Abstract
Keywords
- Adult
- Aged
- Aspirin/administration & dosage/adverse effects
- Double-Blind Method
- Drug Administration Schedule
- Factor Xa Inhibitors/administration & dosage/adverse effects
- Female
- Hemorrhage/chemically induced
- Humans
- Intention to Treat Analysis
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Platelet Aggregation Inhibitors/administration & dosage/adverse effects
- Rivaroxaban/administration & dosage/adverse effects
- Secondary Prevention
- Venous Thromboembolism/mortality/prevention & control
Affiliation
Research group
Citation (ISO format)
WEITZ, Jeffrey I et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. In: New England Journal of Medicine, 2017, vol. 376, n° 13, p. 1211–1222. doi: 10.1056/NEJMoa1700518
Main files (1)
Article (Published version)
Identifiers
- PID : unige:101397
- DOI : 10.1056/NEJMoa1700518
- PMID : 28316279
ISSN of the journal0028-4793
